Immunogenicity and Safety of Rotavirus RV3 Vaccine (Bio Farma) in Neonates
Condition: Rotavirus Gastroenteritis Interventions: Biological: Rotavirus RV3 Vaccine (Bio Farma); Other: Placebo Sponsor: PT Bio Farma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Related Links:
In conclusion, this work gives us a whole panorama of the pre-vaccine era of the RVA molecular epidemiology in the most populated region of Argentina. In this way, this work inspires us to continue with this type of studies in the post-vaccination era.
PMID: 31931256 [PubMed - as supplied by publisher]
Source: Infection, Genetics and Evolution - Category: Genetics & Stem Cells Authors: Mandile MG, Argüelles MH, Temprana CF, Peri Ibáñez ES, Silvestre D, Musto A, Pérez AR, Mistchenko A, Glikmann G, Castello AA Tags: Infect Genet Evol Source Type: research
Purpose of review
Rotavirus is a leading cause of viral acute gastroenteritis in infants. Neonates hospitalized in neonatal intensive care units (NICUs) are at risk of rotavirus infections with severe outcomes. The administration of rotavirus vaccines is only recommended, in the United States and Canada, upon discharge from the NICU despite rotavirus vaccines being proven well tolerated and effective in these populations, because of risks of live-attenuated vaccine administration in immunocompromised patients and theoretical risks of rotavirus vaccine strains shedding and transmission.
We aimed to summarize recent evide...
Source: Current Opinion in Pediatrics - Category: Pediatrics Tags: INFECTIOUS DISEASES AND IMMUNIZATION: Edited by Grace Lee Source Type: research
Vlasova
Rotavirus infection is the major cause of acute gastroenteritis among children globally. Sub-Saharan Africa including Ethiopia is disproportionally affected by the disease. The aims of this review were to determine the pooled prevalence of rotavirus infection among children under-five and to identify the dominant rotavirus genotypes in Ethiopia. Twelve studies were included to estimate the pooled prevalence of rotavirus acute gastroenteritis and five studies were used to determine predominantly circulating genotypes of rotavirus. The pooled prevalence of rotavirus infection was 23% (95% CI = 22%–24%)....
Source: Viruses - Category: Virology Authors: Debasu Damtie Mulugeta Melku Belay Tessema Anastasia N. Vlasova Tags: Review Source Type: research
We examined the effect of RotaTeq® vaccination on rotavirus and all-cause gastroenteritis hospitalisation rates using Poisson regression. Adjusted incidence rate ratios controlled for sex, year of birth, ethnicity, socioeconomic deprivation, and district health board area.
RESULTS: Significant reductions in the incidence of rotavirus hospitalisation were seen in all age groups, ethnicities, and deprivation following the introduction of RotaTeq®. There was a 92.6% reduction in hospitalisation incidence in the vaccinated cohort (p
Source: Vaccine - Category: Allergy & Immunology Authors: McIlhone KA, Best EJ, Petousis-Harris H, Howe AS Tags: Vaccine Source Type: research
Abstract
Rotaviruses are the most common infectious agents causing severe diarrheal diseases in young children globally. Three rare human rotavirus strains, two G3P[9] and one G3P[6], were detected in stool samples of children under 5 years of age hospitalized for gastroenteritis in Lebanon during the course of a surveillance study. Complete genomes of these strains were sequenced using VirCapSeq-VERT, a capture based high-throughput sequencing method. Genomic sequences were further characterized by using phylogenetic analyses with global RVA G3P[6]/P[9] strains, other vaccine and reference strains. Genetic anal...
Source: Infection, Genetics and Evolution - Category: Genetics & Stem Cells Authors: Mishra N, Reslan L, El-Husseini M, Raoof H, Finianos M, Guo C, Thakkar R, Inati A, Dbaibo G, Lipkin WI, Zaraket H Tags: Infect Genet Evol Source Type: research
Condition: Rotavirus Gastroenteritis Interventions: Biological: Rotavirus RV3 Vaccine (Bio Farma); Other: Placebo Sponsor: PT Bio Farma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This study examined the RV vaccine effectiveness against risk of hospitalization based on a retrospective cohort study and the impact of public expense for the RV vaccine on this regional RV gastroenteritis epidemic. The vaccination coverage was significantly higher in children in Shari and Koshimizu than in Abashiri (87.8% vs. 42.7%, respectively, p
Source: Japanese Journal of Infectious Diseases - Category: Infectious Diseases Authors: Sato Y, Yamaki Y, Sasaki Y, Kajino H Tags: Jpn J Infect Dis Source Type: research
Human group A rotavirus is the leading cause of severe acute gastroenteritis in young children worldwide. Immunization programs have reduced the disease burden in many countries. Vaccination coverage in the Au...
Source: BMC Infectious Diseases - Category: Infectious Diseases Authors: Ra úl Pérez-Ortín, Cristina Santiso-Bellón, Susana Vila-Vicent, Noelia Carmona-Vicente, Jesús Rodríguez-Díaz and Javier Buesa Tags: Research article Source Type: research
Conclusions: The present study found RVA positivity in 30.62% of children with gastroenteritis, with the highest burden among 24–36 months old. The predominant genotypes were G1, G3, and P[8]. Further large-scale/multicentric studies should be conducted to document the diversity of circulating RVA genotypes in this region for giving inputs for vaccination strategy.
Source: Journal of Global Infectious Diseases - Category: Infectious Diseases Authors: Arpit Kumar Shrivastava N Samarasimha Reddy Sidhartha Giri Priyadarshi Soumyaranjan Sahu Mirabai Das Nirmal Kumar Mohakud Rashmi Ranjan Das Source Type: research
Authors: Kotsopoulos N, Haitsma G, Connolly MP, Standaert B
Abstract
Background: The economics of rotavirus gastroenteritis in infants
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
